FDA leadership under Dr. Martin Makary emphasizes rapid or instant drug application reviews aided by new generative AI tools such as Elsa. The agency aims to speed regulatory decisions through AI-enhanced document evaluation and propels reforms including biosimilars strengthening and rolling submissions. This approach addresses the need for faster access to medicines and increased efficiency in regulatory pathways, aligning with industry expectations and technological advances.